N. Bonichon-Lamichhane

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

T. Conroy, C. Borg, V. Boige, 2020, Journal of Clinical Oncology.

Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment

J. Lemonnier, M. Campone, O. Coqueret, 2019, Cell Death & Disease.

CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

I. Ray-Coquard, A. Leary, P. Follana, 2020, Clinical Cancer Research.

Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study.

M. Pocard, R. Benamouzig, O. Bouché, 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study

T. Petit, I. Treilleux, I. Ray-Coquard, 2013, Targeted Oncology.

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

T. Conroy, J. Bosset, C. Borg, 2021, The Lancet. Oncology.

GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer

D. Berton, D. Spaeth, E. Kalbacher, 2020, AntiCancer Research.

Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment

J. Lemonnier, M. Campone, O. Coqueret, 2019, Cell Death & Disease.

Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.

D. Berton, I. Ray-Coquard, A. Floquet, 2023, Gynecologic oncology.

304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial

J. Lemonnier, F. Bidard, M. Mouret-Reynier, 2020 .

Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study

C. Lepage, C. Mariette, G. Piessen, 2023, Cancers.

Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial

A. Ginzac, M. Mouret-Reynier, X. Durando, 2024, Breast cancer research and treatment.

Prognostic Value of 18F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE.

K. L. Malicot, N. Bonichon-Lamichhane, G. Tlili, 2024, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.